Beyond Achondroplasia

Growing together with Clara

June 18, 2015
by inesp.alves
1 Comment

BMN-111 – 6 key tidbits

Comments by Mark Schoenebaum, Biotech/Pharma analyst since 2000 MD, Johns Hopkins School of Medicine, 2000 BA, Indiana University, 1995 6 key tidbits:  1)      Phase 3 could enroll 50-100 patients and could be ~1 year in duration. Patient natural history could serve … Continue reading

June 18, 2015
by inesp.alves
2 Comments

Breaking news – BMN-111 Phase 2 proof-of-concept report

Vosoritide is the name we will know from now on. It’s the generic name of BMN-111 Report from the StreetInsider.com BioMarin announced positive results of a Phase 2 proof-of-concept and dose finding study of BMN 111 (vosoritide), an analog of … Continue reading

Translate »